The development of effective treatments that enable many patients suffering from cancer to be successfully cured is highly demanded. Angiogenesis, which is a process for the formation of new capillary blood vessels, has a crucial role in solid tumor progression and the development of metastasis. Antiangiogenic therapy designed to prevent tumor angiogenesis, thereby arresting the growth or spread of tumors, has emerged as a non-invasive and safe option for cancer treatment. Due to the fact that integrin receptors are overexpressed on the surface of angiogenic endothelial cells, various strategies have been made to develop targeted delivery systems for cancer gene therapy utilizing integrin-targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence. The aim of this review is to summarize the progress and prospect of RGD-functionalized nonviral vectors toward targeted delivery of genetic materials in order to achieve an efficient therapeutic outcome for cancer gene therapy, including antiangiogenic therapy.
INTRODUCTION
Cancer is one of the most notorious diseases in the world, and the mortality rate is significantly high. Conventional treatment options, including chemotherapy, radiotherapy, surgery and immunotherapy have shown adverse, nonspecific side effects, which impair successful treatment outcomes for many patients. Non-invasive and safe options for cancer treatment are, therefore, highly demanded.
Gene therapy aiming at the treatment of human disorders by introducing genetic materials into specific target cells or tissues has gained significant attention in the medical community. 1, 2 In particular, gene therapy for cancers has been the most widely studied, and many therapeutic strategies have been utilized, including immune system-targeted therapies (immune-stimulant genes and vaccines) and molecular-targeted therapies (suicide genes, anti-oncogenes and tumor suppressor genes). 3, 4 Owing to the fact that cancers cannot grow beyond a certain size and spread without a blood vessel that provides sufficient supplement such as nutrients and oxygen, as well as pipelines to move out, angiogenesis plays a critical role in solid tumor progression and the development of metastasis. [5] [6] [7] Thus, antiangiogenic therapy designed to prevent tumor angiogenesis has emerged as a non-invasive and safe option for cancer treatment. 8, 9 Furthermore, the fact that angiogenic endothelial cells overexpress integrin cell surface receptors that are known to bind arginine-glycineaspartate (RGD)-containing peptides 10 makes them prime candidates for RGD-based targeted cancer gene therapy. Utilizing RGD motifs mounted by genetic or chemical manipulations, various vectors have been made for the development of targeted delivery systems, including viral vectors 11, 12 and non-viral vectors. 13, 14 Besides viral vectors known for inducing severe immune responses, 15 throughout this review, the progress in developing various RGD-modified nonviral vectors such as polymers, lipids and peptides for use in cancer gene therapy, and specifically antiangiogenic therapy, is summarized. More focus is made on the RGD-modified polymers.
ANGIOGENESIS
Angiogenesis is a process to form new capillary blood vessels from preexisting vasculature. This process is involved in a number of physiological and pathological events. In physiological conditions, it occurs during embryonic development, wound repairing and the menstrual cycle. In pathological conditions, unregulated angiogenesis is seen, such as diabetic retinopathy, rheumatoid arthritis and cancer. 7 The construction of a vesicular network requires several sequential steps, including endothelial cell activation, degradation of the basement membrane, endothelial cell migration, proliferation and stabilization into mature blood vessels. 16 These processes are mediated by a wide variety of angiogenic inducers such as growth factors, chemokines, angiogenic enzymes, endothelial specific receptors and adhesion molecules. 16 The loss of control for cell proliferation is a characteristic of tumor growth. The cancerous cells divide rapidly, resulting in a small, spheroid tumor called in situ carcinoma. 17 Because of the lack of sufficient nutrients and oxygen, in situ carcinomas may remain dormant for many years. Once being switched to angiogenic phenotype, in situ carcinomas induce angiogenesis for tumor expansion, start to invade the surrounding tissues and enter the blood stream to spread throughout the body. Therefore, neovascularization or angiogenesis has a critical role in solid tumor progression and the development of metastasis. related av-integrins show preferential binding to the RGD sequence of the proteins. Short synthetic peptides that contain a RGD sequence mimic the natural ligands. [18] [19] [20] The RGD-integrin recognition is influenced by the conformation of RGD peptides. Cyclic RGD peptides display high binding affinity and specificity for avb3 integrin compared with linear RGD peptides. 13 For example, the cyclic peptide containing two disulfide bonds (ACDCRGDCFCG, single-letter amino acid code), known as RGD4C peptide, was 200-fold more potent than the commonly used linear peptide. 21 The improved binding properties of cyclic RGD peptides arise from structural rigidity. 22 RGD peptides contain an aspartic acid residue, which is highly susceptible to chemical degradation through intramolecular reactions in peptides, leading to the loss of biological functions. 23, 24 The structural rigidity conferred by cyclization prevents the chemical degradation and, consequently, increases the stability of cyclic RGD peptides. However, linear RGD peptides are highly susceptible to chemical degradation, which results in the reduction of binding with integrins. 22 
GENE DELIVERY VECTORS
Among various considerations for the development of gene therapy techniques that can fulfill the requirements of current demands, the lack of safe and efficient gene delivery vectors is a bottleneck by far. Although viral vectors promise an excellent performance in both high efficiency of transfection and great protection of therapeutic genes, safety concerns associated with severe immune and inflammatory responses are the primary obstacle to their clinical application. 1, 15 Various nonviral vectors have been introduced as safe alternatives. In particular, cationic lipids and cationic polymers have gained great interest for their abilities to form a complex with negatively-charged therapeutic genes, to protect genes, and to achieve effective cell entry. [25] [26] [27] [28] Furthermore, the integration of inorganic nanomaterials with cationic polymers creates hybrid vectors that allow not only easy incorporation of genetic materials through electrostatic interactions but also further modifications to be upgraded for image-guided gene delivery with enhanced transgene efficiencies. [29] [30] [31] Nonetheless, the transfection efficiency of nonviral vectors is significantly lower than that of viral vectors. One of the means being explored to achieve the improvement of transfection efficiency is targeted delivery, where therapeutic genes are delivered to selected cells of interest. A wide range of targeting ligands for cancer gene therapy have been incorporated into the nonviral vectors, including folate, 32 Asn-Gly-Arg (NGR) peptides, 33 RGD peptides, 13 transferrins 34, 35 and antibodies. 36, 37 Discussed below are the RGD-modified polymers, lipids and peptides that have been utilized as nonviral vectors for targeted delivery of genetic materials to achieve efficient cancer gene therapy, including antiangiogenic therapy.
RGD-FUNCTIONALIZED POLYMER-BASED VECTORS
PEI-g-PEG-RGD Because of their high buffering capacity, ability to complex with genetic materials and transgene efficacy, polyethylenimines (PEIs) have been the most widely employed as nonviral vectors. 38 Kim et al. [39] [40] [41] prepared PEI-g-PEG-RGD copolymer by conjugating a anb3/anb5 integrin-binding RGD peptide (ACDCRGDCFC, dicyclic form) to a cationic polymer (PEI), with a hydrophilic polyethylene glycol (PEG) spacer (Figure 1a) . [39] [40] [41] The successful complexation of plasmid DNA (pDNA) with the synthetic PEI-g-PEG-RGD polymer was confirmed by agarose gel electrophoresis. Although the size of PEI/pDNA complexes depended on the N/P ratio (the ratio of concentrations of total nitrogen atoms (N) of polycation to the phosphate groups (P) of DNA), the size of PEI-g-PEG-RGD/pDNA complexes was proven to be less affected by the N/P ratio. The particle size of the complexes remained around 100-200 nm within the entire range of N/P ratios from 5 to 10. The cytotoxicity study of PEI-g-PEG-RGD/pDNA complexes using MTT assay on cell applications' dermal microvascular endothelial cells (CADMEC) revealed that PEI-g-PEG-RGD/pDNA complexes were less toxic to CADMEC than PEI/pDNA complexes. The viability of CADMECs incubated with PEI/pDNA was 60% at a N/P ratio of 20, whereas PEI-g-PEG-RGD/pDNA complexes showed over 90% of viability at the same N/P ratio (Figure 2a) . 40 Tumor cells secrete vascular endothelial growth factor (VEGF) that stimulates the transformation of angiostatic endothelial cells into angiogenic endothelial cells, leading to angiogenesis within the tumor. Thus, integrins accumulated at the tumor site through proliferation of angiogenic endothelial cells can be a target for RGD-functionalized vectors carrying therapeutic genes. To confirm the feasibility of targeted delivery, the transfection efficiency of pCMV-luciferase reporter gene complexed with either PEI or PEI-g-PEG-RGD was investigated using a tissue culture model of angiogenesis developed by incubating CADMEC with VEGF. The PEI-g-PEG-RGD/pDNA complexes showed significant enhancement in transfection efficiency over PEI/pDNA complexes, suggesting that integrin-RGD interactions mediated the increased internalization of the complexes. Alternatively, the specificity of RGD-mediated gene transfer was also confirmed using angiostatic CADMECs (normal endothelial cells), revealing lower transfection efficiency of the PEI-g-PEG-RGD/pDNA complexes than that of PEI/ pDNA complexes. 40 In vivo biodistribution of the PEI-g-PEG-RGD vector was studied in a colon cancer animal model (CT-26 mouse colon adenocarcinoma). 41 A therapeutic gene, pCMV-sFlt-1 encoding soluble VEGF receptor 1 as a VEGF antagonist was complexed with either PEI-g-PEG-RGD or PEI-g-PEG, which was then administrated into subcutaneous tumor-bearing mice by i.v. injection. The real-time PCR was assayed for the quantification of pCMV-sFlt-1 copies in various organs. In the case of the group treated with PEI-g-PEG-RGD, it was observed that tissue samples of the heart and the lung contained fewer copies than the tumor, whereas tissue samples of liver, spleen and kidney contained more copies. Other research groups also reported similar results with cationic polyplexes. 42, 43 On the other hand, in the PEI-g-PEG-treated group, all organs showed a greater number of copies than the tumor, except for the kidney. The number of pCMV-sFlt-1 copies in the tumor treated with PEI-g-PEG-RGD and PEI-g-PEG were 7.3% and 0.3%, respectively. A much higher quantity of pCMV-sFlt-1 copies in the case where PEI-g-PEG-RGD vectors were utilized suggests that tumor accumulation of PEI-g-PEG-RGD vectors is much higher than that of PEI-g-PEG vectors, and indicates that RGD peptides are effective for tumor targeting.
The antiangiogenic gene delivery efficiency of PEI-g-PEG-RGD/ pCMV-sFlt-1 complexes was confirmed through in vivo tumorinhibition assay. 41 The PEI-g-PEG-RGD/pCMV-sFlt-1 complexes were administered into CT-26 tumor-bearing mice by i.v. injection. As controls, PEI-g-PEG-RGD/pCMV-GFP complexes (without therapeutic gene) or PEI-g-PEG/pCMV-sFlt-1 complexes (without RGD moiety) were also administrated. Tumors were observed to grow rapidly in the group treated with controls, whereas the growth of tumors was significantly inhibited in the group treated with PEI-g-PEG-RGD/pCMV-sFlt-1 ( Figure 2b ). The inhibition of tumor growth was attributed to the increased accumulation of pCMV-sFlt-1 in the tumor site, demonstrating the importance of targeted delivery.
The successful inhibition of metastatic and primary tumor growth in renal cell carcinoma was accomplished by targeted delivery of a dual expression plasmid, p2CMVIL2/msFlk1, which is composed of genes for interleukin-2 (IL-2, immune-modulating agent) and soluble VEGF receptor 2 (msFlk1, anti-angiogenic agent). 44 The therapeutic plasmid, p2CMVIL2/msFlk1, exhibited similar in vitro transgene expression of IL-2 or msFlk1 compared to its single-agent counterpart (pCMVIL2 or pCMVmsFlk1). To estimate the effect of p2CMVIL2/msFlk1 in an experimental RENCA (renal carcinoma) lung metastases model, therapeutic pDNA complexed with angiogenic endothelial-targeting vector PEI-g-PEG-RGD was systemically delivered. The treatment of p2CMVIL2/msFlk1 in complexed form significantly reduced metastases by 56% over single-agent therapy (pCMVIL2 or pCMVmsFlk1), and the survival proportions were increased by 50% over all groups.
Recently, antiangiogenic gene therapy that targets the silencing of VEGF receptors required for the angiogenic actions of VEGF was reported. 45 The small interference RNA (siRNA) silencing the expression of endothelium-specific receptor tyrosine kinase (fmslike tyrosine kinase or VEGFR1) formed a complex with PEI-g-PEG-RGD vector. The complex was then incubated with SVR cells expressing VEGFR1. The reverse transcriptase PCR assay revealed that the delivery of siVEGFR1 in complexed form induced the inhibition of mRNA of VEGFR1, whereas no reduction was observed for the control that was delivered with silencing luciferase (siLuc). In vivo tumor growth-inhibition studies revealed that CT-26 tumor-bearing mice treated with PEI-g-PEG-RGD/siVEGFR1 complexes through the tail vein resulted in a significant suppression of tumor growth (mean tumor volume: o330 mm 3 after 11 days), whereas tumors in mice treated with a control, PEI-g-PEG/siVEGFR1 complexes, grew rapidly reaching a mean size of over 570 mm 3 after 11 days. The targeted delivery of siRNA to angiogenic vasculature in tumor-bearing mice was also achieved using RGD peptide (ACRGDMFGCA, monocyclic form)-containing PEI polymers (Figure 1b) . 46 siRNA silencing VEGF receptor-2 (VEGF R2) was complexed with PEI-PEG-RGD (monocylic RGD peptide) vector to construct self-assembled nanoparticles. The delivery of siRNA in complexed form inhibited the expression of VEGF receptor-2 (VEGF R2), which resulted in the suppression of tumor angiogenesis. The inhibition of VEGF activities was specific to siRNA sequence and dependent on the presence of RGD peptides. Complexes that were administrated intravenously into tumor-bearing mice were selectively taken up by tumors and caused siRNA sequencespecific inhibition of protein expression within the tumor, leading to the inhibition of tumor angiogenesis and tumor growth.
PEI-S-S-RGD
A thiol-derivatized PEI and a linear RGD peptide (CYGGRGDTP) were conjugated via a disulfide bridge to form a PEI-S-S-RGD vector (Figure 1c) . 47 pDNA was condensed with the PEI-S-S-RGD to afford a homogeneous population of 30-100 nm particles, which were revealed by electron microscopy images. The surface charge of the particles was close to neutral as a consequence of the shielding effect of prominent zwitterionic peptide residues. In vitro transfection studies indicated that the efficiency of PEI-S-S-RGD/ pDNA complexes incubated with integrin-expressing epithelial fibroblast MRC5 under serum conditions was 100 times more effective than that of PEI/pDNA complexes. However, the replacement of just a single residue in the RGD peptide resulted in a reduced targeting efficiency. When the aspartic acid was replaced by a glutamic acid in the targeted peptide sequence (from CYGGRGDTP to CYGGRGETP), no enhancement was observed. However, RGD peptides coupled to PEI through a disulfide linkage turned out to be readily cleaved in the presences of thiols (B50% cleavage in 2-4 h), indicating the uncertainty of the linkage stability in the presence of physiological concentration of thiols. breaking down into low-molecular weight components. [49] [50] [51] Ideally, this feature not only enhances therapeutic outcomes through facilitating intracellular release of therapeutic genes, but also reduces cytotoxicity associated with the molecular weight of cationic polymers. 52, 53 However, these hydrolytically degradable vectors are prone to degrade within the extracellular environment. The instability of these vectors makes them less suitable for gene delivery vectors. As part of continuing endeavors, bioreducible polymers have emerged as promising non-viral vectors. 54 In particular, polymers synthesized via disulfide linkages are of great interest because these vectors are hydrolytically stable in the extracellular environment and capable of being cleaved in the reducing environment. 54 The abundance of reducing agents such as glutathione and thioredoxin reductases inside cells can facilitate intracellular triggering of therapeutic genes complexed with reducing polymers more effectively. 55 As a result, a huge amount of research has been done to develop bioreducible polymeric vectors containing disulfide linkages. 54, 56 Sun et al. 57 introduced a tripeptide sequence RGD onto a reducible polymer through physical adsorption in order to prevent possible reduction or inactivation of the biological activities of RGD peptide arising from a covalent attachment (Figure 1d ). The RGD peptide was added to disulfide-containing PEI (SS-PEI)/DNA binary complexes, and the influence of RGD addition on the particle size, zeta potential, morphology and transfection efficiency was investigated. In vitro studies showed that the cytotoxicity of disulfide-containing vector (SS-PEI 800 Da) was much lower than that of PEI 25 kDa as a control, whereas the transgene expression of SS-PEI/pDNA binary complexes was significantly higher than that of 25 kDa PEI/pDNA complexes. The transfection efficiency of RGD-adsorbed complexes in HeLa cell possessing integrin receptors decreased with the increasing content of RGD peptide, whereas that in 293T cell possessing no integrin receptors was not altered significantly with the increasing content of RGD peptide. The reduction of transfection efficiency of RGD-adsorbed SS-PEI/DNA complexes in HeLa cells was attributed to the blocking of integrin-mediated endocytosis of SS-PEI/RGD/ pDNA complexes by the preferential binding of the integrin receptors on the cell surface to excess RGD peptides that are not adsorbed on the complex or released from the complex in contact with integrins. Although this system improved no tansfection efficiency through a targeted delivery effect, it provides an account of the significance for the chemical attachment of a RGD ligand on the vector.
RGD-PEG-Suc
In general, the positive surface charge of cationic polymer/pDNA complexes facilitates strong electrostatic binding to cell surfaces, which helps to increase the internalization and gene expression on the cultured cells in vitro. 58 However, this cationic charge also elicits uncontrolled adverse interactions with blood cells, 59 serum proteins 43, 60 and extracellular matrices. 61 Therefore, it is needed to produce bio-inert hydrophilic polymers that can shield the positive surface charge in order to achieve in vivo stability. Trubetskoy et al. 62 prepared ternary complexes with a negatively charged surface by adding small amount of polyanion, polyacrylic acid (PAA), to preformed pDNA/polycation complexes. These pDNA/PEI/PAA ternary complexes prevented serum inhibition for transfection in vitro and showed substantially higher gene expression in vivo than pDNA/PEI binary complexes. The enhanced gene expression could be attributed to the decomposition of the ternary complexes by competitive dissociation of the DNA molecule from the polycation upon addition of common polyanions. 63, 64 In order to endow a high stability to polymer/pDNA complexes under physiological conditions, Sakae et al. synthesized an anionic PEG-mercaptosuccinic acid derivative (PEG-Suc) bearing carboxylic acid side chains (Figure 1e without RGD moiety) . 65, 66 It was observed that PEG-Suc could be deposited on the PEI/pDNA complexes without destroying their structures even at high conjugation ratios. Owing to the anionic PEG-Suc coating, the surface of PEI/pDNA complexes was negatively charged, which protected the complexes against serum protein-induced aggregation. PEG-Suc ternary systems displayed a high proton sponge effect between pH 5.5 and 7.4. However, negatively charged surfaces diminished the electrostatic binding of the complexes to the cells, and consequently, the transfection efficiency on cultured B16 cells was not high. RGD peptide side chain was then introduced (Figure 1e ) to confer tumor targeting ability and to compensate for the reduced electrostatic binding. The ternary complexes, pDNA/PEI coated with RGD-PEG-Suc, showed more than 3-fold greater reporter protein activity on the cultured B16 cells. The complexes with RGD ligands displayed very high gene expression in tumor, following injection via tail vein of mice bearing B16 tumor. 66 NPAK-RGD Oishi et al. 67 reported an intracellular signal-responsive gene regulation system using a polycationic polymer (NPAK-RGD) that is composed of poly N-isopropyl acrylamide (NIPAM) as a backbone 41 Reprinted with permission from Elsevier.
and a signal-responsive peptide and a RGD peptide (GRGDS) as side chains (Figure 1f) . A signal-responsive peptide (ALRRASLGW) is cationic and becomes neutral by phosphorylation in response to the cyclic AMP-dependent protein kinase (PKA). In this system, the polycationic polymers formed electrostatic complexes with pDNA. The intention of this system was that once the cationic peptide residues of the complexes are phosphorylated in response to the activation of target protein kinase, the complexes are disintegrated because of the neutralization of the polymer's cationic charge, resulting in the release of pDNA. Thus, the gene expression occurs specifically in the target protein kinaseactivated cells such as colon cancers and breast cancers. 68, 69 In order to study the function of protein kinase activation, the NPAK-RGD/pDNA complexes were applied to agarose gel retardation assay. The migration of pDNA was totally retarded in the absence of activated PKA, while the bands of original pDNA were completely recovered in the presence of activated PKA. This observation suggested that the PKA signal disintegrated the complexes and induced the release of pDNA. In vitro transfection studies in HeLa cells revealed that gene expression of the NPAK-RGD/pLuc complexes with activated PKA was approximately three times higher than that of the same complexes without PKA activation. Transfection efficiencies of the complexes without RGD peptides were less than those of a control (pDNA alone), regardless of PKA activation. 67, 70, 71 Polymeric micelles Polyplex micelles composed of PEG-polycation block copolymers and pDNA have been widely used as nonviral vectors with a potential for systemic applications. [72] [73] [74] The size of these polyplex micelles is B100 nm, which is considered to be optimal for systemic administration. Moreover, these polyplex micelles contain a biocompatible PEG shell layer, which prevents any sort of nonspecific interaction with blood components. To refine their stability and transfection efficiency, disulfide cross-linkages have been introduced, and the resulting polyplex micelles have shown improved transfection efficiencies both in vitro and in vivo mouse models. 75, 76 For the targeted delivery of therapeutic genes into tumor sites, cyclic RGD-installed polyplex micelles were introduced. [77] [78] [79] Thiolated cyclo(RGDfK)-poly(ethylene glycol)-block-poly(L-lysine), (c(RGDfK)-PEG-P(Lys-SH)) (Figure 3a ) underwent spontaneous association with pDNA to form targetable disulfide cross-linked polyplex micelles in aqueous solution. 79 In vitro transfection studies in HeLa cells overexpressing integrin receptors for RGD ligands revealed that the c(RGDfK)-PEG-P(Lys-SH)/pDNA polyplex micelles showed a remarkably increased transfection efficiency compared with the polyplex micelles which contain no targeting moieties (RGD peptide). In a competitive assay where the integrin receptors on the cells are blocked using pre-incubation with free cyclic RGD peptides, the transfection efficiency of the polyplex micelles containing RGD peptides decreased as the concentration of free cyclic RGD peptides increased, demonstrating the receptormediated uptake of the polyplex micelles. The RGD-mediated internalization of polyplex micelles was influenced on a PEG shell layer. 80 PEG (17 kDa)-employed polyplex micelles induced the highest reporter gene expression. For application in antiangiogenic gene therapy, pDNA encoding a soluble form of VEGF receptor-1 (soluble fms-like tyrosine kinase-1: sFlt-1) was complexed with c(RGDfK)-PEG-P(Lys-SH) to form targetable polyplex micelles. 81 Systemic administration of the polyplex micelles into mice bearing BxPC3 human pancreas adenocarcinoma tumors resulted in a significant inhibition of tumor growth up to day 18.
RGD-FUNCTIONALIZED LIPID-BASED VECTORS
In spite of high transfection efficiency, the clinical applicability of viral vectors is limited owing to safety and immunogenic concerns. In an effort to develop vectors that are safe and capable of inducing high gene transfer, researchers have combined viruses and liposomes to create novel vectors that have the high gene transfer efficiency of viral vectors and the biocompatibility of nonviral vectors. 82 However, the large size (400 nm) and the potential concerns associated with the presence of viral proteins in the fused vectors have been a threat to this approach. Instead of employing viral portions, artificial virus-like vectors mimicking viral envelopes that encapsulate genetic materials were introduced. 83 The artificial virus-like envelopes, which were prepared according to the lipid composition of retroviruses, encapsulated pDNA to produce artificial viral particles. To endow targeting ability toward tumor sites, artificial viral particles were equipped with a cyclic RGD peptide (CDCRGDCFC) (Figure 3b) , and the resulting nonviral vectors (RGD-artificial viral particles) transduced endothelial cells with efficiencies of up to 99%. 84 Anwer et al. 85 investigated the transfection efficiency of liposomal vectors based on the configuration of RGD peptides (one and two disulfide bonds) (Figure 3b ). Uptake by human umbilical vein endothelial cells was three times greater for liposomes containing the double disulfide-linked RGD compared with the single disulfide-linked RGD. The lipopeptides containing single or double disulfide linkages were then subjected for gene transfer to human umbilical vein endothelial cellss using DOTMA:-Cholesterol cationic liposomes. Human umbilical vein endothelial cells transfection studies revealed that increasing the mol% of the single disulfide RGD lipopeptide to 20 mol% resulted in 10-fold enhancement of gene transfer.
Thompson et al. 86 prepared lipid vectors composed of a cationic lipid, a neutral lipid and poly(ethylene glycol)-cholesterol. Mixing cationic lipid with pDNA produced a lipoplex with a size of 100 nm. In order to introduce RGD moieties, a lipid-RGD peptide (ACDCRGDCFCG-PEG-cholesterol) was inserted onto the preformed lipoplexes. In vivo targeted gene delivery was achieved in mice bearing PO2 tumors validated for the avb3 integrin expression in the tumor vasculature, showing an increased gene expression.
Another lipid-peptide conjugate, distearoyl phosphoethanolamine-PEG 5000-succinyl-ACDCRGDCFCG-COOH (DSPE-PEG5K-RGD4C) was incorporated into lipid-protamine-DNA (LPD-PEG) lipoplexes to provide tumor-targeting specificity. 87 Introducing DSPE-PEG5K-RGD4C ligands into LPD formulations resulted in a 5-fold and a 15-fold increase in the LPD-PEG-RGD binding and uptake, respectively, compared with the LPD-PEG formulation, leading to a 100-fold enhancement of transfection activity. The transfection enhancement was specific to MDA-MB-231cells expressing integrin receptors, but not to Huh7 cells known for low level of integrin expression.
For better cell selectivity and efficient gene delivery, dualligand-modified liposomes were reported. 88 A cyclic RGD-lipid conjugate (cRGDfk-PEG-DSPE) for tumor targeting and stearylated octa-arginine (STR-R8) functioning as a cell-penetrating peptide were incorporated into the liposome formulation. The resulting dual-ligand-modified liposomes encapsulated pre-condensed pDNA with protamine to produce RGD/R8-PEG-lipoplexes. Compared with control lipoplexes (PEG-lipoplex or each of single ligand-modified lipoplex), RGD/R8-PEG-lipoplexes exhibited a significantly higher level of luciferase gene expression (about 300-fold higher) in human umbilical vein endothelial cells. However, no remarkable difference in transgene levels was observed for skin endothelial cells, where the expression of targeted integrin receptors was absent.
Silencing P-glycoprotein, which is a drug efflux transporter overexpressed on multi-resistant (MDR) tumor cells, is a practical approach to improve MDR tumor therapy. Jiang et al. successfully demonstrated that the tumor growth in mice xenografted with MCF7/A MDR tumor was greatly inhibited by sequential treatment of RGD-modified lipoplexes formed with siRNA, which targets the human MDR1 mRNA, and RGD-modified liposomes containing doxorubicin. 89 
RGD-FUNCTIONALIZED PEPTIDE-BASED VECTORS
Peptides with cationic lysine residues have been widely used as nonviral gene delivery vectors. 90, 91 A potential tumor-targeting peptide vector (cRGD-hK), which was intended to be systemically and repeatedly administered to patients with advanced solid tumors, was developed by Aoki et al. 92 The peptide vector was composed of 36 amino-acid residues, CRGDCF(K[H-]KKK) 6 , incorporating a tumor-targeting RGD motif, a DNA-binding oligolysine and histidyl residues to facilitate the delivery into the cytosol (Figure 3c ). In vitro (hepatoma and pancreatic cancer cells) transfection of the cRGD-hK/pDNA (luciferase expression plasmid) complexes was inhibited in the presence of either bafilomycin A1, which is an inhibitor of the vacuolar ATPase endosomal proton pump, or cycloRGDfV, which is an antagonist for integrin avb3. This indicates the importance of each element in cRGD-hK vectors for in vitro gene transfer. In vivo transfection studies of the cRGDhK/pDNA complexes administrated through the tail vein of nude mice bearing tumors exhibited that the transgene expression in the tumors was significantly higher than that in the lung, kidney and spleen, but only slightly higher than that in the liver.
In another approach, Moore et al. 93 prepared 4-arm PEG-based vectors coupled to DNA-binding peptides and integrin-binding (RGD) peptides (Figure 3d) . Depending on the coupling ratio of DNA-binding peptides and RGDs on to the PEG backbone, different transfection efficiencies were observed in HepG2 cells. Coupling of two RGD peptides and two DNA-binding peptides onto the fourarmed PEG enhanced the transfection efficiency comparable to that of a PEI vector. However, introducing one or three RGD peptides onto the PEG were unable to increase the transfection efficiency. By analysis of the equilibrium and kinetic constants for cell binding and internalization of the complexes, it was found that specific cell binding of the complexes was increased by increasing the number of RGD peptides to the four-armed PEG; however, it did not contribute to the improvement of internalization and transfection efficiency. 94 This might be associated with the fact that high-affinity binding of the particles to the integrin receptors on the cell surface results in extracellular adherence and consequently, low cellular internalization. 95 Therefore, for the PEG vector containing only one RGD peptide, low transfection efficiency could be attributed to the weak specific cell binding of the complexes, resulting in low internalization and low tranfection efficiency. When the PEG vector was coupled with three RGD peptides, the complexes remain on the cell surface because of the strong binding of the complexes to the integrin receptors, which also results in low internalization and low transfection efficiency. Hence, controlling density of RGD peptides on a vector is pivotal for the enhancement of transfection efficiency.
CONCLUDING REMARKS
A vast population of human race is suffering from the lethal disease cancer. The majority of current options for cancer treatments depend on invasive surgery, chemo-and radiotherapy, which cause adverse and nonspecific side effects. Cancer gene therapy aiming at restoring missing functionalities or inducing apoptosis by delivering tumor suppressor genes, anti-oncogenes or suicide genes to the site of tumor has gained significant attention as a non-invasive and safe alternative for cancer treatments. To enhance therapeutic indices and reduce nonspecific toxic effects, various nonviral vectors integrated with integrin-targeting RGD peptides have been introduced and exhibited promising outcomes for cancer gene therapy both in vitro and in vivo.
The targeting ability of the vectors has been well established. The transmembrane mechanism of the vectors was found to be ligand-receptor mediated endocytosis, which was supported by the fact that transfection efficiencies were significantly suppressed by incubating with free RGD peptides as an integrin antagonist. The configuration (linear vs cyclic) and the density of RGD peptides on the surface of a vector/gene complex seem to be important factors in determining their tumor-targeting and transfection efficiency. It has been shown that the affinity of particles to integrin receptors on the cell surface determines whether an integrin-bound particle is internalized or remains on the cell surface. 95, 96 While high-affinity binding to the integrin receptors results in extracellular adherence and consequently low internalization, low-affinity binding induces signal transductions of integrins and subsequent internalization. 95, 96 As the affinity of particles to integrins was affected by the number of RGD peptides that are available for integrin binding on the particle surface, controlling density of RGD peptides on a vector is highly recommended for the enhancement of cellular internalization of a vector/gene complex. The rational design of vectors and controlling density of RGD ligands could provide enhanced therapeutic outcomes for cancer gene therapy. Despite their promising potential, several factors need to be addressed before the vectors are suitable for clinical applications, including in vivo stability, increasing transfection efficiency, lowering possible cytotoxicity associated with utilizing highmolecular-weight polymeric vectors. Bioreducible polymers produced through disulfide linkages from low-molecular-weight polymers or biocompatible polymers mounted with RGD ligands, for example, would be one solution for shortening the time period toward clinical applications.
